| 14.11 -1.19 (-7.78%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.17 |
1-year : | 18.44 |
| Resists | First : | 14.7 |
Second : | 15.78 |
| Pivot price | 14.43 |
|||
| Supports | First : | 12.93 |
Second : | 10.76 |
| MAs | MA(5) : | 14.84 |
MA(20) : | 14.3 |
| MA(100) : | 13.79  |
MA(250) : | 9.68 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 68.1 |
D(3) : | 81.1 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 17.48 | Low : | 3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AMLX ] has closed above bottom band by 33.1%. Bollinger Bands are 38.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.46 - 15.53 | 15.53 - 15.59 |
| Low: | 13.82 - 13.92 | 13.92 - 13.99 |
| Close: | 13.98 - 14.12 | 14.12 - 14.24 |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Tue, 03 Mar 2026
AMLX: Phase III avexitide results expected Q3 2026, with commercialization targeted for 2027 - TradingView
Tue, 03 Mar 2026
Amylyx Pharmaceuticals (NASDAQ:AMLX) Posts Earnings Results, Hits Expectations - MarketBeat
Tue, 03 Mar 2026
Stifel Nicolaus Initiates Coverage on Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
Tue, 03 Mar 2026
AMYLYX PHARMACEUTICALS ($AMLX) Releases Q4 2025 Earnings - Quiver Quantitative
Tue, 03 Mar 2026
Earnings Flash (AMLX) Amylyx Pharmaceuticals Posts Q4 Net Loss $0.30 a Share, vs. FactSet Est of $0.29 Loss - marketscreener.com
Tue, 03 Mar 2026
Amylyx Pharmaceuticals 10-K: $0M Revenue, $(0.29)–$(0.31) EPS range not stated - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 110 (M) |
| Held by Insiders | 8.223e+007 (%) |
| Held by Institutions | 7.5 (%) |
| Shares Short | 13,640 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9297e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 29 % |
| Return on Assets (ttm) | 104.2 % |
| Return on Equity (ttm) | -39.5 % |
| Qtrly Rev. Growth | -665000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -154 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.4 |
| Dividend | 0 |
| Forward Dividend | 1.375e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|